Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Major Shareholder Buys $44,670.00 in Stock

Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) major shareholder Adar1 Capital Management, Llc acquired 3,000 shares of Pieris Pharmaceuticals stock in a transaction that occurred on Friday, August 9th. The stock was purchased at an average cost of $14.89 per share, with a total value of $44,670.00. Following the completion of the purchase, the insider now owns 127,331 shares in the company, valued at approximately $1,895,958.59. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Large shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Adar1 Capital Management, Llc also recently made the following trade(s):

• On Monday, August 12th, Adar1 Capital Management, Llc bought 3,000 shares of Pieris Pharmaceuticals stock. The shares were acquired at an average cost of $15.88 per share, for a total transaction of $47,640.00.

Pieris Pharmaceuticals Trading Up 2.1 %

Pieris Pharmaceuticals stock opened at $16.75 on Thursday. The company has a 50-day moving average price of $11.14 and a 200 day moving average price of $12.26. Pieris Pharmaceuticals, Inc. has a 12-month low of $6.20 and a 12-month high of $41.78. The stock has a market cap of $22.11 million, a P/E ratio of -1.40 and a beta of 0.68.

Pieris Pharmaceuticals (NASDAQ:PIRS) last posted its quarterly earnings results on Wednesday, May 15th. The biotechnology company reported ($3.95) earnings per share for the quarter. Pieris Pharmaceuticals had a negative net margin of 39.71% and a negative return on equity of 57.57%. The firm had revenue of $0.05 million during the quarter.

Hedge Funds Weigh In On Pieris Pharmaceuticals

A hedge fund recently bought a new stake in Pieris Pharmaceuticals stock. Summit Trail Advisors LLC acquired a new position in shares of Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) in the first quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 140,000 shares of the biotechnology company’s stock, valued at approximately $26,000. Summit Trail Advisors LLC owned about 0.14% of Pieris Pharmaceuticals at the end of the most recent quarter. Institutional investors own 40.11% of the company’s stock.

Analysts Set New Price Targets

Separately, StockNews.com began coverage on Pieris Pharmaceuticals in a research note on Friday, July 12th. They set a “hold” rating on the stock.

About Pieris Pharmaceuticals

Pieris Pharmaceuticals, Inc, a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies.